NCT01582217

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

TRIAGE: Patients Undergoing Percutaneous Coronary Interventions to Improve Clinical Outcomes Through Optimal Platelet Inhibition

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 318 (actual)
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the the 1-year rates of ischemic and bleeding complications in patients whose dual antiplatelet therapy regimen post-PCI has been determined with the use of a clinical algorithm that includes both clinical risks and platelet reactivity while on chronic clopidogrel therapy.

Detailed description

Prospective multicenter registry. Patients already on chronic dual antiplatelet therapy with aspirin and clopidogrel will be assessed for (1) clinical risks factors for future bleeding and ischemic complications, and (2) on-treatment platelet reactivity as measured by the VerifyNow P2Y12 assay (Accumetrics, Inc., San Diego, CA, USA). These will be considered by utilization of a clinical algorithm to determine the dual antiplatelet regimen post-PCI (aspirin in combination with 1. clopidogrel, 2. prasugrel 5mg daily, or 3. prasugrel 10mg daily).

Conditions

• Percutaneous Coronary Intervention
• Dual Antiplatelet Therapy
• Aspirin
• Clopidogrel

Timeline

• Start date: 2012-03-01
• Primary completion: 2014-12-01
• Completion: 2014-12-01
• First posted: 2012-04-20
• Last updated: 2015-12-23

Locations

1 site across 1 country: United States